UB641
TargetsPCSK9/LPA
IndicationsAtherosclerotic cardiovascular disease
ClinicalCN - Early Phase
TherapeuticsCardiovascular
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- • Next-generation lipid management product
- • Hit the unmet needs: It can simultaneously reduce two key lipid parameters.
- • Promising in vivo data in NHP: at least comparable to combination efficacy and duration of Inclisiran and internally developed LPA siRNA
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →